Condition: IPF · Idiopathic Pulmonary Fibrosis · Idiopathic Pulmonary Fibrosis (IPF) · Sponsor: SPARK Biopharma
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.
This description comes directly from the study's public registry record.
Seong Yun Bang · +82-2-887-8032 · sybang@sparkbio.co.kr
Yu Jin Choi · +82-2-887-9972 · yjchoi@sparkbio.co.kr
Always discuss trial participation with your own doctor first.
| Myong Ji Hospital | Goyang, South Korea | Recruiting |
| Chung-Ang University Gwangmyeong Hospital | Gwangmyeong, South Korea | Recruiting |
| Seoul Asan Hospital | Seoul, South Korea | Not Yet Recruiting |
| The Catholic Univ. of Korea Seoul St. Mary's Hospital | Seoul, South Korea | Not Yet Recruiting |
| Ajou University Hospital | Suwon, South Korea | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06747923